Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$41.80 USD

41.80
77,369

0.00 (0.00%)

Updated Jul 24, 2024 01:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Hold Varian Medical (VAR) Stock Now

A strong international presence and strategic buyouts aid Varian Medical (VAR); margins pressed.

Quest Diagnostics Rides on Product Launches, Strategic Deals

Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.

STERIS (STE) Dips on New Restructuring Plan, Layoff Decision

STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.

Here's Why You Should Invest in Veeva Systems (VEEV) Now

A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

Chemed's (CHE) subsidiaries continue to register strong sales.

ResMed to Buy Propeller Health, Widens Respiratory Care Suite

Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.

Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds

Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.

Genomic Health (GHDX), BioCartis Extend Deal to Urology

The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.

Zimmer Biomet Rides on New Operational Plan Amid Several Woes

In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.

LabCorp (LH) Stock Declines 10% on Lowered 2018 Guidance

Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

Omnicell (OMCL) continues to witness strong conversion wins for new XT series.

CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing

The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.

QIAGEN's New Offerings to Broaden Hematology Testing Suite

QIAGEN (QGEN) continues to progress with test menu expansion.

Here's Why You Should Invest in Surmodics (SRDX) Right Now

A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.

Varian Medical's (VAR) Halcyon Gets NMPA Approval in China

Varian Medical (VAR) enjoys significant international presence in radiotherapy.

Walgreens Gains from New Alliances, International Expansion

Walgreens Boots (WBA) is benefiting from strategic tie-ups. The Express Scripts and Kroger deals are intended to expand its existing group purchasing efforts and product offerings.

Integra's (IART) Margin Pressure Hurts, Global Prospects High

Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.

Quest Diagnostics to Buy Laboratory Services Unit in Midwest

Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.

CVS Health (CVS) Gets Final Approval to Close Aetna Deal

Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.

Medtronic (MDT) Positive on Mazor Purchase, Rising Costs Ail

The pending acquisition of Mazor Robotics holds great potential as it is likely to solidify Medtronic's (MDT) position in robotic spine surgery.

Align Technology's New iTero Scanner Updates to Boost Uptake

Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.

Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull

Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.

Here's Why You Should Invest in Merit Medical (MMSI) Now

A strong outlook for 2018 and a solid global foothold make Merit Medical (MMSI) a promising investment pick.